Halozyme Therapeutics (NASDAQ:HALO) is one of today's biggest movers, down 12.4% to $6.21. The S&P is currently trading fractionally lower to 1,500 and the Dow Jones Industrial Average is trading fractionally higher to 13,917.

Halozyme Therapeutics is in SmarTrend's Biotechnology industry and this industry is currently in a Downtrend according to our research. We are monitoring many other stocks on the move within this industry.

Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $13.50 and is now at $6.21, 61% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 0.7% while the 50-day MA has advanced 2.4%.

SmarTrend recommended that subscribers consider buying shares of Halozyme Therapeutics on December 21st, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $6.70. Since that recommendation, shares of Halozyme Therapeutics have risen 5.8%. We continue to monitor HALO for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.